Headquartered in Basel, Switzerland, Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz. Following the 2023 spin-off of its Sandoz unit, the company transformed into a “pure-play” innovative medicines leader. It focuses on four core areas: Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, and Oncology. With a 2025 revenue of approximately $54.5 billion, Novartis is aggressively advancing next-generation platforms like Radioligand Therapy (RLT) and xRNA. Despite facing its largest-ever patent cliff in 2026, the company leverages blockbuster growth from Kisqali and Pluvicto to sustain its target of 40%+ core operating margins.
Here are some articles to give you a basic understanding of the company:
Novartis – background and history
Below is a list of articles for the company:
-
Novartis FY25Q4 results
Based on the Novartis Q4 2025 Media Release, here is the high-level summary of the financial and operational performance: Full Year 2025 Financial Results Novartis delivered strong performance in 2025, driven by double-digit growth in core products: Key Growth Drivers (Full Year Sales) The following products contributed significantly to the revenue growth: Pipeline and Strategic…
-
Novartis – History and Competitions
Novartis has a rich history originating from three Swiss companies in Basel, evolving through several distinct stages: 1. The Roots: Three Independent Pioneers (1758–1970) Novartis traces its lineage to three chemical and pharmaceutical firms: Core Products: Core Strategy: Revenue Level: 2. Mergers and the Birth of Novartis (1970–1996) This period marked the transition from chemicals…